NCT04077853

Progesterone in Expectantly Managed Early-onset Preeclampsia

Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Assiut University · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks postpartum

Detailed description

Currently there is no effective treatment for early-onset preeclampsia except for early delivery of the fetus along with the placenta. Progesterone supplementation in the form of 17-alpha-hydroxyprogesterone caproate (17-OHPC) is currently used obstetrically to prevent recurrent preterm birth in patients with pregnancies not complicated by preeclampsia. Previous studies reported that patients with severe PE had significantly lower serum progesterone concentrations than gestational age- and race-matched non-preeclamptics. Moreover, supplementation of placental ischemic rats with 17-OHPC decreased blood pressure, inflammatory cytokines, and ET-1 within 24 hours of treatment

Conditions

• Preeclampsia

Interventions

Type	Name	Description
DRUG	17 Hydroxyprogesterone Capronate	Intramuscular injection 250 mg

Timeline

• Start date: 2019-12-15
• Primary completion: 2021-10-30
• Completion: 2022-01-15
• First posted: 2019-09-04
• Last updated: 2022-05-09

Locations

1 site across 1 country: Egypt